Evidence map›Paper›PMID 33941217›Full record

ArticleSubstance abuse treatment, prevention, and policy2021

Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.

Fatemeh Chalabianloo, Lars Thore Fadnes, Gudrun Høiseth, Christian Ohldieck, Jørn Henrik Vold, Christer Aas, Else-Marie Løberg, Kjell Arne Johansson, Jørgen G Bramness

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fatemeh ChalabianlooDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. fatemeh.chalabianloo@helse-bergen.no.ORCID 0000-0003-1242-1972
Lars Thore FadnesDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Gudrun HøisethDepartment of Forensic Medicine, Oslo University Hospital, Oslo, Norway.
Christian OhldieckDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Jørn Henrik VoldDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Christer AasDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Else-Marie LøbergDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Kjell Arne JohanssonDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Jørgen G BramnessInstitute of Clinical Medicine, UiT - Norway's Arctic University, Tromsø, Norway.
Haukeland University Hospital · NONorwegian Institute of Public Health · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is little evidence-based guidance on how to optimize methadone dosages among patients with opioid addiction undergoing methadone maintenance treatment (MMT). This study aims to investigate whether self-perceived opioid withdrawal symptoms, adverse effects, and self-reported substance use in patients on MMT are related to serum methadone concentrations and the role that these variables could play in clinical decisions on dose adjustments.

methodsThis naturalistic prospective cohort study included clinical and laboratory measurements from 83 patients undergoing MMT in outpatient clinics in Bergen, Norway, from May 2017 to January 2020. Information on age, gender, methadone daily doses and serum concentrations, subjective opioid withdrawal symptoms using 16 items Subjective Opioid Withdrawal Scale (SOWS) questionnaire, self-reported adverse effects, and substance use was obtained. Linear mixed modelling was used for analyzing the data.

resultsThe mean age of the participants was 45 years, and 33% were women. Almost half reported mild to moderate subjective opioid withdrawal symptoms, and all had experienced at least one subjective adverse effect. The use of at least one substance was reported by 88% of the participants. Serum concentration-to-dose ratios were lower among those who had reported subjective opioid withdrawal symptoms (p) = 0.039). The total SOWS score (p < 0.001); the specific subjective withdrawal symptoms of anxiety (p = 0.004), bone and muscle aches (p = 0.003), restlessness (p = 0.017), and (slightly) shaking (p = 0.046), also use of heroin (p = 0.015) and alcohol (p = 0.011) were associated with lower methadone concentrations. Cannabis use was slightly related to higher methadone concentrations (p = 0.049).

conclusionsThe findings suggest that the patient's self-perceived symptoms and current clinical condition are related to the serum concentrations of methadone. This interpretation supports dose adjustments based on patient-reported symptoms. In some aberrant cases, measurement of serum concentrations together with other individual assessments may be considered to support the clinical decision.

Indexed as

MethadoneOpioid-Related DisordersAnimalsCohort StudiesFemaleHumansMiddle AgedOpiate Substitution TreatmentProspective StudiesSwineMethadoneAdverse effectsMethadone maintenance treatmentOpioid agonist treatmentSerum concentrationsSubjective opioid withdrawal symptomsSubstance use

Identifiers

PMID33941217
PMCPMC8091668
OpenAlexW3119974234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.